Anti-inflammatory agent 17 an orally active anti-inflammatory agent, demonstrates potent efficacy in inhibiting the release of IL-6 and TNF-α without causing cytotoxicity in in vitro experiments. Furthermore, in vivo studies confirm its anti-inflammatory activity. Given its attributes, Compound 17 holds promise for investigating Acute lung injury (ALI) [1].

Anti-inflammatory agent 17 (compound 5b) (10 μM; 24 h) displays no toxicity in J774a.1 cells [1]. Anti-inflammatory agent 17 (1.25, 2.5, 5, 10 μM; 2 h) inhibits the production of IL-6 (IC 50 =8.254 μM) and TNF-α (IC 50 =2.576 μM) in J774a.1 cells in a dose-dependent manner [1]. Cell Viability Assay [1] Cell Line: J774a.1 cells Concentration: 10 μM Incubation Time: 24 h Result: Displayed no toxicity in J774a.1 cells. Immunofluorescence [1] Cell Line: J774A.1 cells Concentration: 1.25, 2.5, 5, 10 μM Incubation Time: 2 h Result: Inhibited the production of IL-6 (IC 50 =8.254 μM) and TNF-α (IC 50 =2.576 μM) in J774a.1 cells in a dose-dependent manner.

Anti-inflammatory agent 17 (20 mg/kg; intragastric administration) exhibits protective effect on LPS (lipopolysaccharide)-induced ALI in mice [1]. Animal Model: C57/BL6 mice [1] Dosage: 20 mg/kg Administration: Intragastric administration Result: Exhibited protective effect on LPS-induced ALI in mice.